Insights

Innovative Vaccine Platform HDT Bio is actively developing next-generation vaccine technologies, including RNA and saRNA platforms, targeting infectious diseases and cancers. This focus presents opportunities to collaborate with public health agencies, pharmaceutical partners, and contract manufacturing organizations seeking advanced vaccine solutions.

Strategic Funding & Research With recent awards totaling over 1.7 million dollars from government and industry programs, HDT Bio demonstrates strong backing for its innovative projects. This financial momentum indicates a useful opportunity to offer complementary research services, technology licensing, or additional funding collaborations to accelerate development.

Expansion into Oncology HDT Bio's focus on immunotherapy and development of RNA cancer vaccines broadens its market reach within oncology. Partnering with biotech firms or healthcare providers specializing in cancer treatments can open pathways for joint ventures, licensing, or distribution agreements.

Collaborative Development Models The company's regional partnerships for manufacturing and clinical development, especially in regions like South Africa, suggest openness to strategic alliances. Expanding this model can lead to new collaborations in clinical trials, manufacturing capacity, or market entry strategies.

Growing Financial Profile With a revenue range of 25 to 50 million dollars and ongoing funding, HDT Bio presents an attractive target for investment, strategic partnerships, or supply chain solutions. Engaging with their financial and operational teams could facilitate integrated growth opportunities in biotechnological and immunotherapy markets.

HDT Bio Tech Stack

HDT Bio uses 8 technology products and services including Site Kit, WordPress, Squarespace, and more. Explore HDT Bio's tech stack below.

  • Site Kit
    Analytics
  • WordPress
    Content Management System
  • Squarespace
    Content Management System
  • Open Graph
    Content Management System
  • MySQL
    Database
  • Slick
    Javascript Libraries
  • PHP
    Programming Languages
  • Yoast SEO
    Search Engines

Media & News

HDT Bio's Email Address Formats

HDT Bio uses at least 1 format(s):
HDT Bio Email FormatsExamplePercentage
First.Last@hdt.bioJohn.Doe@hdt.bio
50%
First.Last@hdt.bioJohn.Doe@hdt.bio
50%

Frequently Asked Questions

Where is HDT Bio's headquarters located?

Minus sign iconPlus sign icon
HDT Bio's main headquarters is located at 1150 Eastlake Avenue East 200a Seattle, Washington 98109 United States. The company has employees across 3 continents, including North AmericaAsiaSouth America.

What is HDT Bio's official website and social media links?

Minus sign iconPlus sign icon
HDT Bio's official website is hdt.bio and has social profiles on LinkedInCrunchbase.

What is HDT Bio's SIC code NAICS code?

Minus sign iconPlus sign icon
HDT Bio's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does HDT Bio have currently?

Minus sign iconPlus sign icon
As of March 2026, HDT Bio has approximately 55 employees across 3 continents, including North AmericaAsiaSouth America. Key team members include Co-Founder: N. M.Director Of Virology: J. E.Clinical Trial Manager: J. K.. Explore HDT Bio's employee directory with LeadIQ.

What industry does HDT Bio belong to?

Minus sign iconPlus sign icon
HDT Bio operates in the Biotechnology Research industry.

What technology does HDT Bio use?

Minus sign iconPlus sign icon
HDT Bio's tech stack includes Site KitWordPressSquarespaceOpen GraphMySQLSlickPHPYoast SEO.

What is HDT Bio's email format?

Minus sign iconPlus sign icon
HDT Bio's email format typically follows the pattern of First.Last@hdt.bio. Find more HDT Bio email formats with LeadIQ.

How much funding has HDT Bio raised to date?

Minus sign iconPlus sign icon
As of March 2026, HDT Bio has raised $9M in funding. The last funding round occurred on Feb 16, 2021 for $3M.

When was HDT Bio founded?

Minus sign iconPlus sign icon
HDT Bio was founded in 2018.

HDT Bio

Biotechnology ResearchWashington, United States51-200 Employees

HDT Bio is a vaccine and immunotherapy Biotechnology company developing drugs for immunotherapy of cancers and infectious diseases with next-generation approaches designed to enable the body’s immune system to prevent and cure disease. We have engineered our technologies to Access, Activate, and Amplify the immune system’s natural ability to create antibodies and T-cells that fight cancer and infectious diseases such as SARS-CoV-2. We are developing multiple product candidates from our proprietary discovery platforms, including LION™, which has the potential to provide health benefits to a broad patient population. Our products are designed to be cost-effective solutions to unmet medical needs and complementary to existing, cutting-edge immunotherapies. 

HDT Bio offers a comprehensive compensation plan, which includes health insurance for employees and dependents (inclusive of multiple plans to choose from, including a $0 premium plan with HSA and company contribution), generous PTO (11 observed holidays and week-long year-end closure), stock options with Carta Tax Advisory for equity and tax support, flexible spending accounts (FSAs), commuting benefits (ORCA or paid parking), and retirement benefits with company match. 

HDT Bio Corp. is an equal opportunity employer committed to a diverse and inclusive workforce.

Section iconCompany Overview

Headquarters
1150 Eastlake Avenue East 200a Seattle, Washington 98109 United States
Website
hdt.bio
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2018
Employees
51-200

Section iconFunding & Financials

  • $9M

    HDT Bio has raised a total of $9M of funding over 2 rounds. Their latest funding round was raised on Feb 16, 2021 in the amount of $3Mas a seed.

  • $25M$50M

    HDT Bio's revenue is estimated to be in the range of $25M$50M

Section iconFunding & Financials

  • $9M

    HDT Bio has raised a total of $9M of funding over 2 rounds. Their latest funding round was raised on Feb 16, 2021 in the amount of $3Mas a seed.

  • $25M$50M

    HDT Bio's revenue is estimated to be in the range of $25M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.